HOME >> MEDICINE >> NEWS
GroPep licenses technology to TGR BioSciences

the oral mucositis product. GroPep had decided last year to focus our biopharmaceutical development program on our most desirable products PV903 for recurrent miscarriage and PP0102 for psoriasis and other autoimmune diseases. This arrangement will allow continued development of the WGFE technology by a third party." Dr Leanna Read, Managing Director of TGR said "In addition to the oral mucositis project, this new license combined with intellectual property already held by TGR will allow the company to expand its growing commercial product range in the areas of gut and skin health."

What is Oral Mucositis?

Oral mucositis (mouth ulceration and inflammation) is an extremely painful side effect for many patients undergoing chemotherapy and radiotherapy for cancer. For certain cancer treatments almost all patients suffer from this affliction. Mucositis can be so severe that eating, drinking and speech is not possible. Cancer treatment may have to be delayed or suspended completely and infections originating in the mouth can lead to complications or death. An estimated one million people suffer from oral mucositis each year in the United States.

What is WGFE?

Whey Growth Factor Extract (WGFE) is a biologically active milk extract of naturally occurring proteins known to be fundamental to the tissue healing process.


'"/>

Contact: Tony Mitchell
investorrelations@gropep.com.au
61-883-547-700
Research Australia
26-Jul-2005


Page: 1 2

Related medicine news :

1. GroPep awarded key patent for infertility treatment in Europe
2. GroPep starts Phase 1 infertility trial
3. GroPep completes final milestone of the path malaria vaccine initiative
4. GroPep to pursue promising asthma drug following preclinical study results
5. GroPep news: Key psoriasis patent granted in Japan and new asthma patent filed for GroPep drug
6. Doctors working overseas face having licenses removed
7. UW licenses innovated cardiovascular software to VPDiagnostics
8. The Wistar Institute licenses rubella vaccine seed stock to Microgen of Russia
9. MCW Research Foundation licenses invention for stroke treatment
10. Wireless technology shows promise in diagnosing pediatric intestinal disease
11. Speeding up CT scans with cellphone technology, ultrasound warning signal for breast cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/18/2019)... ... April 18, 2019 , ... ... Beverly Hills that offers a full menu of cosmetic and general dental care ... expertise in biomimetic dentistry, which relies on minimally-invasive techniques in restorative dentistry. Biomimetic ...
(Date:4/17/2019)... ... April 17, 2019 , ... With Fentanyl overdose deaths continuing to claim ... the death toll by looking for an alternative to naloxone. Researchers are presenting their ... this week. , Naloxone (often known by the name brand Narcan) has been utilized ...
(Date:4/17/2019)... ... April 17, 2019 , ... Purple ... symptoms. This California-made supplement was designed to lessen the negative effects of ... for purchase via GotPurpleTree.com and Amazon.com . , According to ...
(Date:4/17/2019)... , ... April 17, 2019 , ... Signaled.online is a ... available for users: alarm, monitoring of the web resources and reminder. , The alarm ... as if you live alone. If you haven’t logged in to the website for ...
(Date:4/17/2019)... ... 17, 2019 , ... Nastel Technologies is a premier global ... for mission-critical applications in the mixed cloud environments. Nastel is entering its 25th ... MQ. , Nastel XRay® for MQ, a Big Data analytics platform for AIOps, ...
Breaking Medicine News(10 mins):
(Date:4/17/2019)... ... 2019 , ... Dr. Srini Pillay, a best-selling author, neuroscientist, tech entrepreneur and ... subverting ideas on creativity and the processes behind human thinking. He recently wrote on ... share his thoughts on social media and the suppression of the human voice. , ...
(Date:4/17/2019)... CHARLOTTE, N.C. and ATLANTA, Ga. (PRWEB) , ... ... ... provider of financial solutions to healthcare providers and patients, announced today it has ... not disclosed. , Founded in 2012, Omni Holdings is the leading medical lien ...
(Date:4/17/2019)... ... April 17, 2019 , ... ... for diseases involving mitochondrial dysfunction, announced yesterday at the 2019 Muscular Dystrophy ... and open-label extension (OLE) clinical trial evaluating efficacy of elamipretide, an investigational ...
Breaking Medicine Technology:
Cached News: